Index

Abciximab, 99–100, 171–173, 238–239
acute coronary syndrome and, 152, 154
-induced thrombocytopenia (AIT), 104
ISAR-REACT trial, 267
ACC/AHA Guidelines, 88
Acetaminophen (paracetamol), 43
Acetylsalicylic acid. See also Aspirin
adverse effects, 39–40
pharmacodynamics, 38–39
pharmacokinetics, 37–38
structure, 37
Acquired non-allergic hypersensitivity, 40
ACUITY-TIMING study, 156
ACUITY trial, 138
Acute coronary syndromes
aspirin and, 145–147, 266
dual oral antiplatelet therapy and, 64
glycoprotein IIb/IIIa receptor
inhibitors, 188
adjunctive therapy, 157
and CABG, 156–157
conservative strategy, 151–153
invasive strategy, 153–156
upstream use prior to revascularization, 156
heparins and antiplatelet agents in, 133–136
thienopyridines
bleeding risk, 149
clopidogrel, 149–150
drug interaction, 150
oral antiplatelet agent withdrawal,
150–151
randomized evidence, 147–149
without ST elevation, 145–157
ACUTE II, 136
Acute ischemic stroke, 224–225
Adenosine, 8
Adenosine diphosphate (ADP), 59, 60–63, 111
Adenosine triphosphate (ATP), 114
Adrenaline, 6
African American Antiplatelet Stroke
Prevention Study, 220
Andersen, K., 52
Antithrombotic therapy, 61
Arachidonic acid, 7, 35
Arg-Gly-Asp (RGD) sequence, 98
Arterial thrombosis, ADP and, 60
ASCET (ASpirin non-responsiveness and
Clopidogrel Endpoint Trial), 55
Aspirin
acute coronary syndrome and, 145–147
acute ischemic stroke therapy, 224–225
antiplatelet effects of, measuring, 48
aspirin resistance, 47–55, 146–147
clinical relevance of, 50–54
definitions of, 48, 53
future directions in studies of, 55
Aspirin (continued)
  mechanisms of, 49–50
  prevalence of, 50
  bleeding risk, 146, 256
  CABG and stable CAD, 234–235
  cardiovascular risk reduction and, 197–199, 251–252
  combined with clopidogrel, for acute coronary syndromes, 217
  coronary heart disease prevention, 216
  coronary stents
    aspirin pretreatments, 266
    post implant therapy, 270–271
  drug interactions, 147
  dual antiplatelet therapy, 77, 184–187, 251–252
  gastrointestinal intolerance of, 146
  history of, 33
  hypersensitivity to, 146
  ischemic stroke prevention, 215
  peripheral arterial disease and, 197–201
  platelet aggregation and, 116
  recurrent ischemic stroke and, 218–222
  response variability, 47
  STEMI and, 164–165, 172
  stent thrombosis and, 253, 259
  versus ticlopidine, 63–64
ASSENT-3, 131
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3, 131
Atherosclerotic disease
  direct oral inhibitors and, 68–69
  therapy in perioperative period, 256
Atherosclerotic lesions, 10
A to Z trial, 136
AZD6140, 59–60, 68–71
  coronary artery disease and, 181, 191
  in perioperative period, 257
  unstable coronary artery disease and, 69, 70
Bavry, A.A., 254
Bertrand, O.F., 106
Biondi-Zoccaie, G.G.L., 255
Bivalirudin, 53, 138, 157
Bleeding time, 15, 18
Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial, 221
Buch, A.N., 54
Buchner, Johann, 33
BX667, 112, 114, 117
Cangrelor, 112, 114
  in acute coronary syndromes, 116
  in animal studies, 117–118
  in human studies, 118–119
CAPRIE trial, 64, 146, 148, 181, 202, 203, 220
CAPTURE trial, 154
Cardiovascular disease, aspirin therapy and, 52
Cardiovascular system, COX-2 inhibitors and, 43
Cerebrovascular diseases and antiplatelet therapy
  acute ischemic stroke, 224–225
  ischemic stroke, 215–218
  recurrent ischemic stroke, 218–222
  warfarin versus antiplatelet agents, 222–223
CHAMPION-PCI trial, 120
CHARISMA trial, 184, 186, 202, 204, 220, 235
Chen, W.H., 52, 53
Chinese Acute Stroke Trial, 224
Cigarette smoking
  aspirin resistance and, 49
  clopidogrel resistance and, 81
Cilostazol, 189–190, 205–207
CLEAR PLATELETS studies, 88
Clopidogrel
  acute coronary syndrome and clopidogrel resistance, 150
dose/timing of, 149–150
bleeding risk, 149, 240–241
CABG
and stable CAD, 234–236
and unstable CAD, 236–239
CHARISMA trial, 184, 186, 202, 204, 220, 235
clinical benefit of, 59
clinical relevance of nonresponsiveness, 86–87
coronary artery bypass grafts and, 242–243, 244
coronary stents and, 271
discontinuation risk in non-cardiac surgery patients, 255
ischemic risk in nonresponsiveness to, 86–88
lab evaluation of responsiveness, 79–80
limitations of therapy using, 77
long-term therapy with coronary stents, 271–275
management of clopidogrel resistance, 88
mechanism of action, 78–79
mechanism of resistance, 81–85
PCI and, 253
pretreatment with coronary stents, 266–268
P2Y12 inhibitors and, 112
resistance, 53, 79
resistance studies, 81, 82
STEMI and, 165–168, 169, 173
studies, 60
and ticlopidine compared, 111–112
unstable coronary artery disease and, 69, 70
Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, 217
Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial, 64, 146, 148, 181–183, 202, 203, 220
Cochrane Collaboration Review, 205
COMMIT, 217
COMMIT/CCS-2 trial, 167–168, 173
Coronary artery bypass surgery (grafting), 233–245
aspirin resistance and, 49
aspirin therapy
stable CAD and, 234–235, 241–242
in unstable CAD patients, 236–239, 242–245
benefits of, 233
bleeding and antiplatelet therapy in, 239–241
aspirin, 239–240
aspirin and clopidogrel, 240–241
glycoprotein IIb/IIIa inhibition, 241
clopidogrel and, 235
combined antiplatelet therapy, 235–236
GP IIb/IIIa antagonists, 238–239
GP IIb/IIIa inhibitors and, 156–157
novel potential strategies, 236
in patients with stable CAD, 234–236
in patients with unstable CAD, 236–239
“quadruple therapy,” 239
risks of, 233
Coronary artery disease
ADP receptor antagonists
clopidogrel, 181–183
novel agents, 183
ticlopidine, 181
antiplatelet therapy after PCI in, 190
aspirin therapy, 178–181, 191
after previous myocardial infarction, 178–179
aspirin resistance, 181
dosing considerations, 180
interaction with NSAIDs, 180–181
without previous MI, 180
CAPRIE trial, 181–183
Coronary artery disease (continued)
cilostazol, 189–190
dipyridamole, 189
direct oral inhibitors and, 69
dual antiplatelet therapy, 184–187
oral glycoprotein IIb/IIIa inhibitors, 187–189

See also Stent thrombosis

periprocedural antiplatelet therapy
aspirin pretreatment, 266
clopidogrel pretreatment, 266–268
glycoprotein IIb/IIIa inhibitors, 268–270
postprocedural antiplatelet therapy
aspirin after stent implant, 270–271
clopidogrel after stent implant, 271
long-term clopidogrel therapy, 271–272
long-term clopidogrel/very late ST, 272–275

COX-inhibiting nitric oxide donors (CINODs), 43
CREATE trial, 136
CREDO trial, 190, 253, 266–267, 271, 272, 275
CREST study, 87

Critical Leg Ischaemia Prevention Study (CLIPS), 197, 199
CRUSADE Initiative 2004, 237, 241, 242
CURE trial, 146, 147–148, 217, 237, 239,
242, 266, 270
Cyclic adenosine monophosphate (cAMP), 60

Cyclooxygenase (COX)
function and tissue expression, 35–37
inhibitors, 33–44
acetyl salicylic acid, 37–38
historical development of, 33–34
non-selective NSAIDs, 40–42
selective COX-2 inhibitors, 42–43
uncategorized, 43
isoforms of, compared, 34
structure, 34–35
variants, 37

Cyclopentyltriazolopyrimidines, 68
CYP3A4 and CYP3A5, 150

Dextran, 265
Diabetes therapy
clopidogrel, 84
PCI, 269

Dipyridamole, 221, 222, 223
coronary artery disease therapy, 189
coronary stents and, 265, 266
ischemic stroke prevention, 215
platelet aggregation and, 116

Dipyrone, 43
Direct thrombin inhibitors, 136–139
DISPERSE-2 trial, 69, 70

Dorsch, M.P., 54

Drug-eluting stents, 190, 253–254, 260–261
Dual antiplatelet therapy, 64, 77
bleeding risk, 256–257
peripheral arterial disease and, 205
stent thrombosis prevention, 257–259, 265
for stent thrombosis prevention, 253

EARLY-ACS trial, 156
Eikelboom, J.W., 52

Eisenstein, E.L., 273
Endarterectomy for asymptomatic stenosis trials, 218

Endothelial COX-1, 8
Enoxaparin, 135, 136

EPIC trial, 269
EPILOG trial, 238, 241, 269
Epinephrine, 6

EPISTENT trial, 103, 238, 241, 268

Eptifibatide, 153, 155, 171, 268–269
Eptifibatide, 99, 100–101

ESPRIT trial, 103, 221
ESSENCE trial, 135, 136
European Atrial Fibrillation Trial, 222

European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT), 103, 221

European Stroke Prevention Study 2, 220–221
Femoropopliteal revascularization, 205–206
Ferrari, E., 255
Fibrinogen, 98, 99
Fibrinolysis and platelets, 128–131
Fibrinolytic agents, 125–131
Fibrinolytic therapy, 164, 167, 169
Fondaparinux, 157

Gastrointestinal system
ASA toxicity and, 39
aspirin and hemorrhage risk, 216
COX-2 inhibitors and, 42
NSAIDs and, 41
Genetics, response to antiplatelet drugs and, 50
Glycoprotein IIb/IIIa complex, 4
alternative dosing strategies, 106–107
intracoronary administration, 106–107
Glycoprotein IIb/IIIa inhibitors, 169, 171–172
acute coronary syndrome and adjunctive therapy, 157
CABG and, 156–157
conservative strategy, 151–153
invasive strategy, 153–156
upstream use prior to revascularization, 156
acute ischemic stroke therapy, 224
BRAVO trial, 221
coronary artery bypass surgery and, 238
coronary artery disease treatment, 187–189
percutaneous coronary intervention and, 266
periprocedural antiplatelet therapy, 269–270
Glycoprotein IIb/IIIa receptors
abciximab, 99–100
beneficial clinical effects of, 103
contraindications, 105–106
detrimental clinical effects of bleeding, 103–104
cross-administration of, 105
pulmonary alveolar hemorrhage, 105
re-administration, 105
thrombocytopenia, 104–105
development of, 98–99
efficacy measurement of, 102–103
epitifibatide, 100–101
pharmacology of intravenous, 97–107
platelet physiology and, 97–98
snake venom and, 99
tirofiban, 101–102
GOLD study, 102
GRACE registry, 242
Granules, 3–4, 9
Grotemeyer, K.H., 50
Grundmann, K., 50
Gum, P.A., 52, 53
Gurbel, P.A., 270
GUSTO trials, 131, 137, 152, 242
Heart Protection Prevention Evaluation (HOPE) trial, 52
Hemostasis, 60
Heparin, 157, 239, 265
and antiplatelet agents in ACS patients, 133–136
and fibrinolytic agents, 126
-HIT, 104, 132
-platelet interaction, 132
UA/NST-elevation myocardial infarction and, 127
Hirudin, 137
Hobikoglu, G.F., 53
Hoffman, Felix, 33
HOPE trial, 52
Hypersensitivity to ASA, 40
NSAIDs and, 42
Iloprost, 236
Impact® cone and plate(let) analyzer, 22–23
IMPACT-II, 103, 268
Indobufen, 236
INS50589, 112, 114, 117
INTERACT trial, 136
Interruption claudication, 52
International Stroke Trial, 224
Intra-arterial thrombosis, 111
Intracranial hemorrhage risk, 40
ISAR, 239, 265
ISAR-CHOICE study, 88
ISAR-REACT trial, 154, 267
Ischemic stroke, 215–218
acute ischemic stroke, 224–225
CAPRIE trial, 182
recurrent ischemic stroke, 218–222
ISIS-2 trial, 164
JUMBO-TIMI 26 trial, 65
Ketoconazole, 83
Laboratory aspirin resistance. See Aspirin
Large-vessel intracranial disease, 222–223
Lesion revascularization, 253
Lev, E.I., 53
Light transmittance aggregometry, 80, 102
Lipophilic statins, 83–84
LMWH, 133–134, 135, 157
Lys-Gln-Ala-Gly-Asp-Val sequence, 98
Management of Atherothrombosis With Clopidogrel in High-Risk Patients with TIA or Stroke (MATCH) trial, 220
Marcucci, R., 53
Marmur, J.D., 106
MATCH trial, 220
Milrinone, 206
Moser, M., 130
Mueller, M.R., 52
Multicenter Acute Stroke Trial-Italy, 224
Myocardial infarction
antiplatelet therapy and, 265–266
aspirin therapy, 178–179
Myocardial Infarction Trial–Second Chinese Cardiac Study, 130
Naftidrofuryl, 209
Nitric oxide, 7, 236
Non-cardiac surgery, 251–261
coronary stents and, 257–259
patients without coronary stents, 259–260
in perioperative period, 256–257
rationale for, 251–254
recently stented patients and, 260–261
risks of discontinuation of, 251, 254–256
Non-ST-segment elevation myocardial infarction, 266
Norepinephrine, 6
NSAIDs (non-steroidal anti-inflammatory drugs)
aspirin resistance and, 49
coronary artery disease and, 180–181
drug interactions, 147
minimizing toxicity of, 43
non-selective, 40–42
prostaglandin synthesis and, 33
traditional (non-COX selective), 37
OASIS-5 study, 157
Paclitaxel-eluting stent, 255, 270, 272
Paracetamol, 37, 43
PCI-CURE study, 266, 272, 275
Pentoxifylline, 207–208
Percutaneous balloon angioplasty, 52
Percutaneous coronary intervention (PCI), 52, 59
antiplatelet therapy following, 190
dual antiplatelet therapy and, 253
dual oral antiplatelet therapy and, 64
P2Y12 inhibitors and, 111
stent implantation and, 252–253
Percutaneous transluminal angioplasty, 266
Peripheral arterial disease (PAD), 196–210
alternative antiplatelet agents, 209
aspirin
cardiovascular risk reduction, 197–199
claudication and limb-related outcomes, 199
guidelines/recommendations, 200–201
patency following revascularization, 199–200
CAPRIE trial, 182
cilostazol, 205–207
pentoxifylline, 207–208
thienopyridines
  cardiovascular risk reduction, 201–203
  claudication and limb-related outcomes, 203–204
  guidelines/recommendations, 205
  patency following revascularization, 204–205
Persantine-Aspirin Reinfarction Studies (PARIS), 189
Peters, R., 270
PFA-100®, 23–24
PGE2, 8
P-glycoprotein, 84
Phencoumon, 150
Phosphatidyl inositol-3 kinase (PI-3K) activity, 60
Physicians Health Study, 199
Picotamide, 209
Platelet Function Analyzer, 23–24, 50
Platelets
  activated at site of injury, 112–113
  adhesion/initiation of thrombus formation, 6
  aggregometry, 18–19
  arachidonic acid pathway/thromboxane A2, 7
  bleeding time, 15, 18
  coronary atherothrombosis and, 9–10
degranulation, 61
  and direct thrombin inhibitors, 136–139
  effects of P2Y12 inhibitors on aggregation of, 116–117
  fibrinolysis and, 128–131
  functional responses, 3–4, 5
  glycoprotein IIb/IIIa complex, 4, 97–98
  granules contained in, 3
  heparin/platelet interaction, 132
  inflammatory responses of, 9
  lab assessment, 15–27
  platelet activation/coagulation cascade, 125–128
  P2 receptors, 6
  procoagulant activity, 8–9
protease-activated receptors (PARs) and thrombin, 7
  receptor pathways inhibiting activation of, 7–8
  whole blood flow cytometry, 24–26
PLATO trial, 69, 71
PPACK, 100
Prasugrel, 59, 64–68, 84, 89
  coronary artery disease and, 183, 191
  STEMI and, 171
  stent thrombosis and, 67
  TRITON-TIMI trial, 221
  in vivo antiplatelet potency of, 65
Prevention Regimen for Effectively avoiding Second Strokes (PROFESS) trial, 222
Primary percutaneous coronary intervention (PCI), 164
Primary stroke prevention, 216–217
PRISM-PLUS trial, 135, 153
PRISM trial, 153
PROFESS trial, 222
Prostacyclin, 7–8
Prostaglandin H synthase 1 (COX-1), 35
Prostaglandin H synthase 2 (COX-2), 36
Prostanoids, 36
Protease-activated receptors (PARs), 7
PRT060128, 112, 114, 117
P-selectin, 116–117
Pseudothrombocytopenia, 104–105
Pulmonary alveolar hemorrhage, 105
PURSUIT trial, 238, 268
P2X1 receptor, 6, 60
P2Y12 inhibitors, 6, 59–71
  as antithrombotic drug target, 60–61
  cangrelor and clopidogrel interaction, 114–115
  clinical trials, 115–121
  direct oral inhibitors, 59, 68–71
  in experimental thrombosis, 61
  intravenous, 111–121
  animal studies, 117–118
  human studies, 118–119
  pharmacology of, 112–115
  platelet aggregation and, 116–117
  prasugrel, 59, 64–68
P2Y_{12} inhibitors (continued)
role of, in platelet activation, 62
thienopyridines, 59–68
clinical utility, 63–64
mode of action of, 61–63

Streptokinase, 224
Stroke. See Ischemic stroke
Sulfinpyrazone, 215
Sulocitidil, 215
SYNERGY trial, 135, 136

RANTES, 9
Rapid Platelet Function Assay (RPFA), 102
Recurrent ischemic stroke, 218–222
RELAX-AMI, 172
Renal system
COX-2 inhibitors and, 43
NSAIDs and, 41–42
REPLACE-2 trial, 138
RESTORE trial, 155
Reviparin, 136
Rifampin, 81

Salicylic acid, 37–38
SCAAR study, 273
Second International Study of Infarct Survival Study, 217
Sirolimus-eluting stent, 255, 270, 272
St. Johns Wort, 81
STARS study, 265
SYNERGY trial, 135, 136

Salicylic acid, 37–38
SMAA study, 273
Second International Study of Infarct Survival Study, 217
Sirolimus-eluting stent, 255, 270, 272
St. Johns Wort, 81
Synergy trial, 265

Thienopyridines, 59–68
acute coronary syndrome and bleeding risk, 149
clopidogrel dose/timing, 149–150
clopidogrel resistance, 150
drug interaction, 150
oral antiplatelet agent withdrawal, 150–151
randomized evidence, 147–149
adenosine diphosphate and, 111
cardiovascular risk reduction, 201–203
clopidogrel, 61–64, 78–88
peripheral arterial disease and, 201–205
prasugrel, 64–68, 84, 89
response variability and resistance, 77–89
STRI and, 165–168, 169–171
stent thrombosis and, 253
structures, 62
symptomatic atherothrombosis and, 252
ticlopidine, 61–64
Thrombelastography, 80
Thrombin, 7, 10, 132
Thrombin receptor agonist peptide (TRAP), 101
Thrombocytopenia, 61, 104–105
Thromboelastograph (TEG), 21
Thrombolysis in Myocardial Infarction (TIMI) 14 trial, 131
Thrombopoietin, 3
Thromboxane A_{2}, 7
Ticlopidine
acute coronary syndrome and, 147
clinical utility, 63–64
and clopidogrel compared, 111–112
ischemic stroke prevention, 215
mode of action, 61–63
P2Y$_{12}$ inhibitors, 112
studies, 59, 60
Ticlopidine Aspirin Stroke Study (TASS), 219–220
TIMI trials, 136, 137
Tirofiban, 99, 101–102, 153, 155, 171, 269
and UFH comparisons, 133, 135
TITAN-TIMI 34 trial, 171
Triflusal, 209
TRITON-TIMI 38 study, 67–68, 148–149, 170, 221–222, 241
TXA$_2$, aspirin resistance and, 48
UFH therapy, 132, 134
Ultegra Rapid Platelet Function Assay, 54

VerifyNow®, 19–21
VerifyNow Aspirin, 18, 20, 53, 54
VerifyNow GP IIb/IIIa Assay, 20
VerifyNow P2Y$_{12}$ receptor assay, 20, 24, 80
von Willebrand factor (VWF), 6

Warfarin, 150, 222–223
Warfarin Aspirin Recurrent Stroke Study (WARSS), 222
Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial, 223
Whole blood flow cytometry, 24–26
Women’s Health Study, 216

Vane, Sir John, 33
Vasodilator-stimulated phosphoprotein (VASP), 60